Company: RGNT
Filing Date: 2025-01-24
Form Type: DRS
Source: 0001213900-25-006245
Chunk: 267

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-24
Form: DRS
Chunk 267
---
 US.

In addition, in the event the Company
is unable to have its convertible notes converted as planned or their repayment date deferred, the Company will not have sufficient cash
flows and liquidity to finance its business operations as currently contemplated. If such sufficient financing or payment deferral is
not received timely, the Company would then need to pursue a plan to license or sell its assets, seek to be acquired by another entity,
cease operations and/or seek bankruptcy protection. The Company’s financial statements do not reflect any adjustments that might
result from the outcome of this uncertainty.

| d. | Impact of the “Iron Swords” War on Israel |

In October 2023, Hamas terrorists infiltrated
Israel’s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Following the attack,
Israel’s security cabinet declared war against Hamas and commenced a military campaign against Hamas and other terrorist organizations
in parallel to their continued rocket and terror attacks. In addition, Hezbollah have attacked military and civilian targets in Northern
Israel, to which Israel has responded, including through increased air and ground operations in Lebanon. Since the war broke out, our
operations have not been adversely affected by this situation, and we have not experienced disruptions to our development. However, the
intensity and duration of Israel’s current war against Hamas and Hezbollah is difficult to predict at this stage, as are such war’s
economic implications on the Company’s business and operations and on Israel’s economy in general. The Company continues to
monitor its ongoing activities and will make adjustments in its business if needed, including updating any estimates or judgments impacting
its financial statements as appropriate.

| NOTE 2:- | SIGNIFICANT ACCOUNTING POLICIES |

| a. | Basis of presentation: |

The financial statements have been prepared
in accordance with accounting principles generally accepted in the United States (the “U.S. GAAP”).

<div align='center'>F-23</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 2:- | SIGNIFICANT ACCOUNTING POLICIES (Cont.) |

| b. | Use of estimate in preparation of financial statements: |

The preparation of financial statements
in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in
the financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions. The Company’s